100
NPS
Learn More about Brand Intelligence Solutions
Find out what hundreds of thousands of customers are saying about your brand, your competitors and others in the industry
Thank you for inquiring about Comparably's Brand Intelligence Solutions
A member from Comparably's team member will be reaching out shortly to set up a time to speak about our Brand Intelligence Solutions
Brand Page
Celldex Therapeutics
Marketing or Exec? Claim Your Free Account
About Celldex Therapeutics' Brand
Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system Among its major competitors, Celldex Therapeutics is ranked in 1st place for NPS while Biogen is 2nd, and Agenus is 3rd.Their current market cap is $903.61M
Celldex Therapeutics Ranking
- #1 / 4 of its competitors
Celldex Therapeutics NPS
Celldex Therapeutics's Net Promoter Score (NPS) is a 100 with 100% Promoters, 0% Passives, and 0% Detractors. Net Promoter Score tracks whether Celldex Therapeutics's customers would recommend using the product based on a scale of -100 to 100.
Celldex Therapeutics Overall NPS
| 100% | Promoters |
|---|---|
| 0% | Passives |
| 0% | Detractors |
Celldex Therapeutics NPS Trend
-100
-50
0
50
100
| Summary | Date | Score |
|---|---|---|
Apr 2023 100 | Apr 2023 | 100 |
How Other Brands Compare
Celldex Therapeutics is ranked first for NPS among its competitors. Biogen and MyoKardia come in second and third, with Reata Pharmaceuticals coming in at #4. Among those competitors, it is the lowest valued company behind Biogen.
Celldex Therapeutics |  Biogen |  MyoKardia |  Reata Pharmaceuticals | |
| Global Ranking | #- | #388 | #- | #- |
| NPS | 100 | 21 | - | - |
| Social Sentiment Calculated by analyzing social media and other online mentions | - | Neutral | Neutral | - |
| Valuation Updated every 24 hours for public companies | $903.61M | $42.46B | $11.99B | $2.95B |
What is NPS
Net Promoter Score (NPS) is a management tool that can be used to gauge the satisfaction of a firm's customer relationships. NPS has been widely adopted as a key metric often linked to the revenue potential of a company’s product or service. The metric is based on customer responses to the question: "On a scale of 0 to 10, how likely are you to recommend the product to a friend?"
Those who respond with a score of 9 to 10 are known as Promoters, and are widely associated with behaviors that create value, including actively encouraging others to use the product or service. Those who respond with a score of 7 or 8 are categorized as Passives, and they are believed to be less likely to exhibit the value-creation traits of Promoters having a largely neutral effect on other consumers. Detractors are those who fall in the score range of 0 to 6 and represent dissatisfied customers of the product sometimes actively recommending against using the product.
Celldex Therapeutics NPS vs. Competitors
Compared to its competitors, Celldex Therapeutics's NPS is rated right above Biogen.
| COMPANY | NPS Score | |
|---|---|---|
| Celldex Therapeutics | 100 |
| Biogen | 21 |
 | Agenus | N/A |
| MyoKardia | N/A |
| Reata Pharmaceuticals | N/A |
Consumer vs. Employees
Celldex Therapeutics scored a 100 for Net Promoter Score and a 0 for Employee Net Promoter Score. NPS gauges how likely a customer of Celldex Therapeutics would recommend the brand to a friend. ENPS measures how likely Celldex Therapeutics employees would recommend working at Celldex Therapeutics to a friend.
Net Promoter Score
100
NPS Score
| 100% | Promoters |
|---|---|
| 0% | Passive |
| 0% | Detractors |
Employee Net Promoter Score
0
eNPS Score
| 0% | Promoters |
|---|---|
| 100% | Passive |
| 0% | Detractors |
